Clinical Significance of Cytokeratin 19 Mrna in the Peripheral Blood of Non-Small Cell Lung Cancer
YU Hui,HUANG Xiu-ying,WANG Xin,WANG Jun-ye,LU Bin,YANG Han,ZHANG Lan-jun,FU Jian-hua
DOI: https://doi.org/10.3760/cma.j.issn.1673-4904.2011.01.007
2011-01-01
Abstract:Objective To evaluate the clinical significance of cytokeratin19(CK19) mRNA in the peripheral blood of patients with non-small cell lung cancer (NSCLC). Methods The expression of CK19 mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR) in the peripheral blood from 98 NSCLC patients (NSCLC group), 20 benign pulmonary lesion patients (benign pulmonary lesion group) and 20 healthy adults(control group). Results The positive rate of CK19 mRNA in peripheral blood of NSCLC group, benign pulmonary lesion group and control group was 77.55 % (76/98), 3.57% (1/28),0 (0/20) respectively,and there was significant difference among three groups ( x2 = 73.680,P < 0.01 ). The positive rate of CK19 mRNA in different pathological types of NSCLC had no significant difference (x2 =0.414, P > 0.05 ), but had significant difference in different lymphy node metastasis status( x2 = 17.523, P <0.01 ) and different clinical stage ( x2 =13.453,P < 0.01 ). Conclusions The higher expression of CK19mRNA in peripheral blood of NSCLC may relate to cancer metastasis. Detection of CK19 mRNA has significance in early prediction of its prognosis.